← All trials
NCT03332303
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2017
- Primary completion
- Mar 15, 2018
- Completion date
- Mar 15, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 538
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Prasco LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.